



**European  
Society of  
Hypertension**




**THE FOUNDATION  
of the European Society of Hypertension**

# 12<sup>th</sup> Official pre-ESH Congress Satellite Symposium



## DIFFICULT TO CONTROL HYPERTENSION & RELATED COMORBIDITIES



**Scientific Program**



Hellenic Society  
of Hypertension



ESH Working Group  
Interventional treatment  
of Hypertension



University of Athens  
School of Medicine



Hellenic Cardiological Society  
Working Group  
Arterial Hypertension



Institute for Study, Research  
Education & Therapy of Vascular,  
Heart, Brain, Kidney, Nephrologies



1st Department of Cardiology,  
University of Athens,  
Hippocratic Hospital



Cardiology Department,  
General Hospital of Athens  
"LAIKO"

**Focused sessions on Renal Denervation  
and ESH Research projects with the  
participation of ESH WGs  
and Excellence Centers**

[www.acardio-ekpa.gr](http://www.acardio-ekpa.gr)  
[www.inaken.gr](http://www.inaken.gr)  
[www.dromena.gr](http://www.dromena.gr)

# 13-14 March 2026

Benaki Museum **Amphitheater**

138 Piraeus Street, **ATHENS**

**DROMENA**  
MEETINGS & EVENTS

## **Chairman**

**K. Tsioufis (GR)**

## **Co-chairman**

**R.E. Schmieder (DE)**

## **Local Organizing Committee**

**K. Dimitriadis (GR)**

**M. Doulas (GR)**

**E. Gkaliagkousi (GR)**

**A. Kasiakogias (GR)**

**A. Kollias (GR)**

**D. Konstantinidis (GR)**

**K. Kyriakoulis (GR)**

**E. Manios (GR)**

**M. Marketou (GR)**

**P. Sarafidis (GR)**

**G. Stergiou (GR)**

**F. Tatakis (GR)**

**C. Thomopoulos (GR)**

## Editorial

Dear Colleagues,

We are really very happy to welcome you again in Athens at the **12th Official pre-ESH International Congress Satellite Symposium**, titled **“Update on difficult to Control Hypertension and Related Comorbidities”**, on **13 - 14 March 2026** at the Benaki Museum Amphitheater (Piraeus Street).

We are looking forward to your participation to the meeting that continues to maintain its own distinct characteristics: interactive with short duration of presentations and assignment of one panelist per speaker, dedicated sessions to pharmacotherapy and renal denervation for management of uncontrolled hypertension in light of the recently released ESH and ESC Hypertension guidelines and session dedicated to ESH Research Projects with active involvement of leaders of ESH Excellence Centers.

Participants who take care of hypertensive patients (Cardiologists, Internists, Nephrologists and General Practitioners) after completion of the Symposium will be able to transform into clinical practice the medical knowledge shared in the meeting, leading to better hypertension management.

Participate, learn and live the experience of the 12th Official pre-ESH Congress Satellite Symposium in Athens 13 - 14 March 2026.

With warm regards,

**Kostas Tsioufis**



**Chairman of the Symposium  
President of ESH (2017-2019)**

**Roland E. Schmieder**



**Co-Chairman of the Symposium**

**Thomas Weber**



**President of ESH (2024-2026)**

# FINAL SCIENTIFIC PROGRAM

UPDATE ON DIFFICULT TO CONTROL HYPERTENSION AND RELATED COMORBIDITIES

**Friday March 13, 2026**

## 09.00-10.30 ATHENS MEDICAL DEGREE AND NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS SESSION

*What is essential for a medical student about hypertension*

*Chairpersons: A. Kasiakogias (GR), A. Kollias (GR), E. Manios (GR), A. Protogerou (GR)*

Accurate measurement of blood pressure

**G. Hadjizacharias (MD)**

Evaluation and exclusion of secondary hypertension

**D.P. Savvides (MD)**

Estimation of cardiovascular risk in patients with hypertension

**K.M. Soliman (MD)**

Blood pressure thresholds and treatment targets

**N.S. Coppinger (MD)**

Lifestyle modification as first-line management

**M. Elsherbiny (MD)**

Pharmacological treatment of hypertension

**A. Alexandrou (MD)**

Interventional therapies for hypertension

**I. Chaudhari (MD)**

*Discussants: A. Karagianni (MD), A. Koutsakis (MD), N. Machairas (MD), A. Orfanou (MD), M. Minagia (MD), G. Botis (MD)*

## 10.30-11.30 WORKSHOP I: A brief update in the pathophysiology of essential HTN (5 mins / presentation)

*Coordinators: Tm. Makris (GR), D. Papadopoulos (GR), C. Grassos (GR)*

Introductory Lecture: Physical inactivity and hypertension (7 mins / presentation)

**A. Pittaras (GR)**

Obesity

**E. Siafi (GR)**

Steatosis

**N. Kakouri (GR)**

Aortic stiffness

**M. Poikilidou (GR)**

Stress and depression

**K. Ntalekou (GR)**

Sodium consumption

**I. Tsoumpou (GR)**

Potassium supplements

**C. Filipou (GR)**

Alcohol abuse

**A. Menti (GR)**

SNS overactivity

**M. Sagris (GR)**

Air pollution

**N. Stamataki (GR)**

Narcotic substances

**M. Stathoulopoulou (GR)**

Anticancer drugs

**E. Manta (GR)** 

# Friday March 13, 2026

## 11.30-12.30 **ROUND TABLE I: Uncontrolled hypertension and related disorders (I)** (6 mins / presentation - 2 mins / panelist)

*Chairpersons:* **D. Farmakis (GR), E. Liberopoulos (GR), E. Oikonomou (GR)**

How to diagnose OSA in a hypertensive patient

**K. Cholidou (GR)**

CPAP and BP outcomes

**I. Zamanis (GR)**

RDN and BP outcome in OSAS

**K. Papadomarkaki (GR)**

Pharmacological weight-loss strategies and BP control

**E. Liberopoulos (GR)**

Procedural weight-loss options and BP control

**E. Kallistratos (GR)**

When and how to treat high triglycerides in an obese hypertensive patient

**I. Andrikou (GR)**

*Panelists:* **A. Angelis (GR), D. Gourlis (GR), M. Divani (GR), A. Papastamatis (GR), C. Liakos (GR)**

## 12.30-13.30 **ROUND TABLE II: A dive in Cardiovascular Imaging in hypertension** (6 mins / presentation - 2 mins / panelist)

*Chairpersons:* **K. Aggeli (GR), A. Kitsiou (GR), M. Marketou (GR)**

Mild hypertrophy. Hypertensive or athletic heart?

**A. Kasiakogias (GR)**

The left atrial adaptations in hypertension

**D. Klettas (GR)**

Key echo findings in HFpEF

**I. Dimitroglou (GR)**

Stress echo. When and why

**I. Ntalakouras (GR)**

Renal artery/abdominal aorta imaging. When and how

**G. Georgiopoulos (GR)**

Carotid artery ultrasonography. When and how

**D. Terentes-Printzios (GR)**

CT coronary angiography. When and why

**A. Antonopoulos (GR)**

*Panelists:* **I. Liatakis (GR), M. Kouremeti (GR), N. Karaminas (GR), D. Peponaki (GR), A. Ifantis (GR),**

**I. Kachrimanidis (GR), C. Kaskoutis (GR)**

## 13.30-14.00 **LUNCH BREAK**

## 14.00-15.00 **ROUND TABLE III: Update on Stroke and Hypertension management** (8 mins / presentation)

*Chairpersons:* **E. Manios (GR), C. Savopoulos (GR), H. Triantafyllidi (GR)**

Blood pressure variability in acute stroke patients

**E. Manios (GR)**

Isolated aortic systolic hypertension: too many evidence that cannot be neglected any more

**A. Protogerou (GR)**

Should I close a PFO in a hypertensive patient after a TIA?

**M. Palkopoulou (GR)**

Malignant hypertension and stroke

**A. Argyris (GR)**

Prognosis of emergency /urgency hypertension

**C. Fragoulis (GR)**

*Questions from the fellows:* **G. Mathaiopoulos (GR), A. Menti (GR), E. Paschalopoulos (GR),**

**P. Kostakis (GR), N. Pirpiris (GR)**

## Friday March 13, 2026

### 15.00-16.05 **ROUND TABLE IV: Uncontrolled Hypertension and related disorders (ii)** (8 mins / presentation)

Chairpersons: **E. Gkaliagkousi (GR)**, **A. Postadzhiyan (BG)** 🌐, **C. Thomopoulos (GR)**

The role of inflammation in the pathogenesis of microcirculatory disease in hypertension

**A. Virdis (IT)** 🌐

Hypertension in women of reproductive age

**E. Gkaliagkousi (GR)**

Prognosis of women with a history of hypertensive disorders in pregnancy

**A. Lazaridis (GR)**

GLP1-RAs and Hypertension: mechanisms and evidences

**L. Sorodoc (RO)**

Kidney disease and hypertension. How possible is the regression of albuminuria and kidney damage?

**R. Kalaitzidis (GR)**

*Evolution in the combination treatment*

**M. Marketou (GR)**

*Questions from the fellows:* **A. Lazarou (GR)**, **K. Mavromoustakou (GR)**, **M. Chatzi (GR)**

**G. Koutsopoulos (GR)**, **E. Tziouva (GR)**

### 16.05-17.00 **ROUND TABLE V: Secondary hypertension. Key issues** (7mins / presentation)

Chairpersons: **A. Januszewicz (PL)**, **D. Petras (GR)**, **H. Triantafyllidi (GR)**

Fibromuscular dysplasia and spontaneous coronary artery dissection: facets of the same disease or distinct enemies?

**A. Persu (BE)**

Primary aldosteronism: Screening and diagnosis

**M. Doulas (GR)**

Endocrine and drug-induced hypertension

**A. Triantafyllou (GR)**

Polycystic kidney and hypertension

**A. Damianaki (GR)**

*Questions from the fellows:* **G. Gompos (GR)**, **D. Soureli (GR)**, **E. Kalliakouda (GR)**, **A. Vordoni (GR)**

### 17.00-17.15 **COFFEE BREAK**

### 17.15-17.45 **SATELLITE LECTURE - AstraZeneca**

### 17.45-18.45 **ROUND TABLE VI: Optimizing management of Difficult-to-Control Hypertension in 2026**

(10 mins / presentation)

Chairpersons: **M. Azizi (FR)**, **G. Stergiou (GR)**, **D. Lovic (RS)**

Pseudoresistance, adherence and patient preference

**A. Pathak (FR)** 🌐

Prognostic implications of resistant hypertension

**A. Januszewicz (PL)**

Current role of digital tools and cuff less BP monitoring devices

**G. Parati (IT)**

Is the therapeutic approach based on the current HTN GDLS effective?

**K. Tsioufis (GR)**

Panelists: **A. Koumeli (GR)**, **K. Konstantinou (GR)**, **A. Menti (GR)**

# Friday March 13, 2026

**18.45-19.30 PODIUM DISCUSSION:** *Starting the discussion for the next edition of HTN guidelines* (5 mins / presentation)

*Coordinators:* **G. Mancia (IT)**, **T. Weber (AT)**, **C. Delles (UK)**, **R.E. Schmieder (DE)** 

**What was the unique characteristic of the current HTN GDLs. An expert view**

2023 ESH GDLs

**C. Thomopoulos (GR)**

2024 ESC GDLs

**A. Kollias (GR)**

2025 AHA/ACC GDLs

**D. Konstantinidis (GR)**

*Panelists:* **G. Parati (IT)**, **M. Doulas (GR)**, **G. Stergiou (GR)**, **E. Agabiti-Rosei (IT)**, **A. Januszewicz (PL)**,  
**G. Grassi (IT)**

## 19.30-20.15 HONORARY LECTURES

*Chairpersons:* **K. Tsioufis (GR)**, **G. Stergiou (GR)**, **G. Parati (IT)**

Diagnosis and treatment of hypertension: Which BP should be the reference?

**G. Mancia (IT)**

RNA-Based therapies for hypertension

**M. Azizi (FR)**

Treatment of diabetic and hypertensive kidney disease: from a dead-end to open avenues

**P. Sarafidis (GR)**

20.15

**OPENING CEREMONY**

# Saturday March 14, 2026

## 09.00-10.00 **SESSION I: Hypertension and heart failure with preserved ejection fraction: An update** (8 mins / presentation)

*Chairpersons:* **E. Agabiti-Rosei (IT), M. Camafort (ES), C. Chrysochoou (GR)**

Can we define “hypertensive cardiomyopathy”?

**T. Weber (AT)**

The increasing importance of exercise testing in the characterization of patients at high risk of HFpEF

**S. Masi (IT)**

Myocardial fibrosis in HFpEF: From imaging to therapies

**A. Kasiakogias (GR)**

The right heart in hypertensive heart disease and HFpEF. Time to bring it to the forefront

**I. Leontsinis (GR)**

Cardiorenal protection in patients with Cardiovascular-Kidney-Metabolic syndrome: Drug options at hand

**M. Camafort (ES)**

Guideline recommendations for hypertensive patients with HFpEF. Time for an update?

**E. Agabiti-Rosei (IT)**

Does RDN has a role in the management of HFpEF?

**P. Iliakis (GR)** 

*Panelists:* **M. Marketou (GR), M. Drakopoulou (GR), D. Konstantinidis (GR), M. Kouremeti (GR),**

**C. Grassos (GR), E. Karanikola (GR)**

## 10.00-10.30 **SESSION II: Uncontrolled hypertension and atrial fibrillation. A case based discussion** (8 mins / presentation)

*Chairperson:* **A. Kordalis (GR), D. Tsiachris (GR)**

Rhythm control. When and how

**P. Tsioufis (GR)**

Rate control. When and how

**C. Antoniou (GR)**

Combined interventional approach for HTN and AF

**I. Doundoulakis (GR)**

*Panelists:* **N. Argyriou (GR), M. Botis (GR)**

## 10.30-11.00 **COFFEE BREAK**

## 11.00-14.00 **SESSION III: Success of a RDN program. The structured referral pathway is a MUST (I).**

*Recent worldwide multidisciplinary experience*

*Chairpersons:* **M. Azizi (FR), G. Stergiou (GR), K. Tsioufis (GR), Weil J. (DE)**

The UK Proposal (4 mins)

**K. Dimitriadis (GR)**

The Canadian Proposal (4 mins)

**E. Sanidas (GR)**

The Asian Proposal (4 mins)

**F. Tatakis (GR)**

The Greek Proposal (6 mins)

**D. Konstantinidis (GR)**

The H-RDN registry/ The H-RDN platform (4 mins)

**P. Tsioufis (GR) , Th. Makris (GR)**

Saturday March 14, 2026

## Discussion

### With Representatives of the Contributing scientific societies

Hellenic Society of Hypertension

**P. Sarafidis (GR), M. Doulas (GR)**

Hellenic Society of Cardiology

**L. Michalis (GR), G. Triantis (GR), G. Tsigkas (GR)**

Hellenic Society of Nephrology

**S. Panagoutsos (GR) , D. Petras (GR) **

Hellenic Academy of General Practice

**E. Fragoulis (GR), A. Mariolis (GR)**

### With Representatives of Greek ESH Excellence centers

AHEPA Hospital, Thessaloniki

**A. Triantafyllou (GR)**

ALEXANDRA Hospital

**E. Manios (GR)**

ATTIKON Hospital

**H. Triantafyllidi (GR)**

HIPPOCRATIO Hospital, Athens

**D. Konstantinidis (GR), A. Kasiakogias (GR)**

Irakleio, Crete

**M. Marketou (GR)**

LAIKO Hospital

**C. Thomopoulos (GR)**

METROPOLITAN Hospital, Athens

**E. Kallistratos (GR)**

NIKAIA, AGIOS PANTELEIMON, Athens

**R. Kalaitzidis (GR)**

PAPAGEORGIOU Hospital, Thessaloniki

**E. Gkaliagkousi (GR), V. Kotsis (GR)**

SOTIRIA Hospital

**A. Kollias (GR), G. Stergiou (GR)**

HIPPOCRATIO Hospital, Thessaloniki

**M. Doulas (GR), P. Sarafidis (GR)**

### With Representatives of the Greek Cath Labs

AHEPA Hospital, Thessaloniki

**M. Didagelos (GR) , A. Ziakas (GR) **

Ioannina University Hospital

**D. Nikas (GR) , L. Michalis (GR),**

**C. Katsouras (GR) **

ALEXANDRA Hospital

**D. Papoutsis (GR)**

Asklipio Hospital

**L. Poulimenos (GR)**

ATHENS MEDICAL CENTRE

**P. Altzitzoglou (GR), A. Taleb (GR)**

ATTIKON Hospital

**G. Karamasis (GR) , I. Xenogiannis (GR)**

ELPIS Hospital

**P. Stougiannos (GR)**

Erythros Stavros

**I. Tsiafoutsis (GR)**

Evangelismos Hospital

**A. Trikas (GR), A. Zacharoulis (GR)**

G. GENNIMATAS Hospital

**D. Avramidis (GR), K. Raisakis (GR)**

G. PAPANIKOLAOU General Hospital of Thessaloniki

**I. Zarifis (GR) **

Henry Dunant Hospital

**J. Kanakakis (GR)**

HIPPOCRATIO Hospital, Athens

**K. Aznaouridis (GR), E. Dri (GR), G. Latsios (GR),**

**A. Papanikolaou (GR), S. Soulaïdopoulos (GR)**

HIPPOCRATIO Hospital, Thessaloniki

**C. Papadopoulos (GR) , V. Vasilikos (GR) **

KAT

**N. Kafkas (GR)**

LAIKO Hospital

**I. Paizis (GR), E. Sanidas (GR)**

MEDITERRANEAN

**A. Magginas (GR)**

METROPOLITAN GENERAL

**A. Kolyviras (GR)**

NAYTIKO HOSPITAL

**G. Katsimagklis (GR), A. Mastrokostopoulos (GR),**

**A. Milkas (GR)**

NEA IONIA, Hospital

**S. Patsilinas (GR)**

NIMITS

**E. Koutoulakis (GR)**

Continued

Saturday March 14, 2026

## Discussion

SOTIRIA Hospital

**K. Kalogeras (GR), G. Vlachogiannis (GR)**

Thriasio Hospital

**A. Dagle (GR)**

Tzaneio

**G. Gavrielatos (GR), N. Patsourakos (GR)**

University General Hospital of Alexandroupoli

**D. Tziakas (GR)** 

University General Hospital of Larisa

**I. Skoularigkis (GR)**

University General Hospital of Patras

**A. Karanasos (GR), M. Papafaklis (GR)**

University General Hospital of Irakleio, Crete

**M. Chamilos (GR)** , **S. Petousis (GR)** 

**E. Skalidis (GR)** 

YGEIA

**M. Koutouzis (GR)**

251 Military hospital

**A. Marinakis (GR)**

401 Military Hospital

**D. Antoniadis (GR), K. Konstantinou (GR)**

### With Representatives of the Primary Healthcare structures in the ATTICA Region

Lavrio Health Center

**P. Papageorgaki (GR), A. Gkikas (GR)**

Koropi Health Center

**A. Fekas (GR), E. Georgakila (GR), E. Tsetsekou (GR)**

Spata Health Center

**I. Karamelas (GR), E.I. Papadima (GR)**

Vari Health Center

**P. Sklavounos (GR), Z. Chrona (GR)**

Markopoulo Health Center

**P. Mandolas (GR)**

Alexandras Health Center

**G. Gastouniotis (GR)**

Dafni's Health Center

**K. Papakostopoulos (GR)**

Rafina's Health Center

**M. Daoukou (GR)**

Megara Health Center

**A. Korakidou (GR)**

14.00-14.30 **LIGHT LUNCH**

14.30-15.30 **SESSION IV: Success of a RDN program (ii): Procedural aspects, device selection, long term follow up**

*Chairpersons:* **J. Weil (DE), A. Ziakas (GR)** , **T. Weber (AT)**

RDN by using the spiral RF system

**K. Tsioufis (GR)** (5mins / presentation)

RDN by using the Paradise ultrasound system

**K. Dimitriadis (GR)** (5mins / presentation)

No-Touch Ultrasound Renal Denervation with TIVUS: Clinical Data, Safety and Trial Design

**J. Weil (DE)** (5mins / presentation)

Device-Related Adverse Events and Modes of Failure in Renal Denervation Systems: Insights From the Food and Drug Administration Manufacturer and User Facility Device Experience (FDA MAUDE) Database Analysis

**K. Kyriakoulis (GR)** (4mins / presentation)

Long-term effects of renal denervation on hypertension management: Insights from an ESH center of excellence and a meta-analysis of current evidence

**S. Soulaïdopoulos (GR)** (4mins / presentation)

*The view of interventional Cardiologists:* **N. Kafkas (GR), K. Kalogeras (GR), G. Latsios (GR),**

**A. Papanikolaou (GR), L. Poulimenos (GR), E. Sanidas (GR), A. Synetos (GR), G. Triantis (GR),**

**E. Dri (GR), K. Aznaouridis (GR), D. Venetsanos (GR)**

# Saturday March 14, 2026

## 15.30-16.30 **PODIUM DISCUSSION: Pleiotropic effects of RDN** (4 mins / presentation)

*Chairpersons:* **K. Narkiewicz (PL), V. Kotsis (GR), L. Sorodoc (RO)**

In chronic kidney disease

**D. Kannenkeril (DE)**

On dialysis patients

**Th. Makris (GR)**

On coronary microcirculation /coronary artery

**K. Dimitriadis (GR)**

On capillary density /retinal

**L. Nikolopoulou (GR)**

On erectile dysfunction

**K. Platanias (GR)**

In the lipid profile

**I. Andrikou (GR)**

On glucose metabolism

**E. Koutra (GR)**

On gut microbioma

**A. Vakka (GR)**

On emergency hypertension

**I. Vassiliadis (GR), C. Fragoulis (GR)**

On proteomics

**D. Polyzos (GR)**

On stress and anxiety. The ERSAM Randomized study

**F. Tatakis (GR)**

## 16.30-17.30 **SESSION V: Blockade the RAAS in the management of uncontrolled HTN. The key role of aldosterone**

*Chairpersons:* **G. Parati (IT), A. Januszewicz (PL), V. Kotsis (GR)**

Aldosterone dysregulation in hypertension and aldosterone synthase inhibition

**M. Azizi (FR)** (12 mins / presentation)

Aldosterone synthase inhibitors for blood pressure reduction in CKD

**F. Iatridi (GR)** (8 mins / presentation)

The HEBRO randomized trial

**P. Iliakis (GR)**  (6 mins / presentation)

*Panelists:* **R. Kalaitzidis (GR), M. Poikilidou (GR)**

## 17.30-17.45 **COFFEE BREAK**

## 17.45-18.30 **3 short lectures and 3 hot topics** (15 mins / presentation)

*Chairpersons:* **M. Camafort (ES), M. Dumas (GR), D. Tousoulis (GR)**

Social disparities in hypertension

**C. Delles (UK)**

Sympathetic overdrive in resistant hypertension: from single studies to a meta-analysis

**G. Grassi (IT)**

Can we use arterial stiffness in clinical routine?

**T. Weber (AT)**

## Saturday March 14, 2026

### 18.30-19.15 SESSION DEDICATED TO ESH RESEARCH PROJECTS (ESH WGS AND EXCELLENCE CENTERS INITIATIVES). THIS SESSION IS SUPPORTED BY SERVIER

*Chairpersons:* **T. Weber (AT), A. Persu (BE), E. Gkaliagkousi (GR)**

Survey on awareness and management of hypertensive heart disease (HHD) and heart failure with preserved ejection fraction (HFpEF) among European Society of Hypertension Excellence Centres

**A. Kasiakogias (GR), S. Masi (IT), M. Camafort (ES)**

An update on ABPM during and after COVID-19 pandemic

**A. Januszewicz (PL)**

Emergency hypertension registry

**C. Fragoulis (GR)**

Malignant hypertension (HAMA) registry

**R. Boulestreau (FR)** 

FEIRI study - ongoing projects

**A. Persu (BE)**

The dominant role of hypertension in HECMOS 1 and 2 snapshots

**G. Koutsopoulos (GR)**

The Hevro Project. The echo ad proteomics data

**M. Kouremeti (GR), S. Drogaris (GR)**

Cost effectiveness of renal denervation: A systematic review and meta-analysis

**K. Kyriakoulis (GR)**

AI and ECG for prediction of hypertension

**K. Fragkiadakis (GR)**

19.15

### **CLOSING REMARKS**

**K. Tsioufis (GR)**

## FACULTY

Agabiti-Rosei E. (IT)	Grassos C. (GR)	Makris Tm. (GR)	Sagris M. (GR)
Aggeli K. (GR)	Hadjizacharias G. (MD)	Mancia G. (IT)	Sanidas E. (GR)
Alexandrou A. (MD)	Iatridi F. (GR)	Mandolas P. (GR)	Sarafidis P. (GR)
Altzitzoglou P. (GR)	Ifantis A. (GR)	Manios E. (GR)	Savopoulos C. (GR)
Andrikou I. (GR)	Iliakis P. (GR)	Manta E. (GR)	Savvides D.P. (MD)
Angelis A. (GR)	Januszewicz A. (PL)	Marinakis A. (GR)	Schmieder R.E. (DE)
Antoniadis D. (GR)	Kachrimanidis I. (GR)	Mariolis A. (GR)	Siafi E. (GR)
Antoniou C. (GR)	Kafkas N. (GR)	Marketou M. (GR)	Skalidis E. (GR)
Antonopoulos A. (GR)	Kakouri N. (GR)	Masi S. (IT)	Sklavounos P. (GR)
Argyriou N. (GR)	Kalaitzidis R. (GR)	Mastrokostopoulos A. (GR)	Skoularigkis I. (GR)
Argyris A. (GR)	Kalliakouda E. (GR)	Mathaiopoulos G. (GR)	Soliman K.M. (MD)
Avramidis D. (GR)	Kallistratos E. (GR)	Mavromoustakou K. (GR)	Sorodoc L. (RO)
Azizi M. (FR)	Kalogeras K. (GR)	Menti A. (GR)	Soulaidopoulos S. (GR)
Aznaouridis K. (GR)	Kanakakis J. (GR)	Michalis L. (GR)	Sourelis D. (GR)
Botis G. (MD)	Kannenkeril D. (DE)	Milkas A. (GR)	Stamataki N. (GR)
Botis M. (GR)	Karagianni A. (MD)	Minagia M. (MD)	Stathoulopoulou M. (GR)
Boulestreau R. (FR)	Karamasis G. (GR)	Narkiewicz K. (PL)	Stergiou G. (GR)
Camafort M. (ES)	Karaminas N. (GR)	Nikas D. (GR)	Stougiannos P. (GR)
Chamilos M. (GR)	Karampelas I. (GR)	Nikolopoulou L. (GR)	Synetos A. (GR)
Chatzi M. (GR)	Karanasos A. (GR)	Ntalakouras I. (GR)	Taleb A. (GR)
Chaudhari I. (GR)	Karanikola E. (GR)	Ntalekou K. (GR)	Tatakis F. (GR)
Cholidou K. (GR)	Kasiakogias A. (GR)	Oikonomou E. (GR)	Terentes-Printzios D. (GR)
Chrona Z. (GR)	Kaskoutis C. (GR)	Orfanou A. (MD)	Thomopoulos C. (GR)
Chrysochoou C. (GR)	Katsimagklis G. (GR)	Paizis I. (GR)	Tousoulis D. (GR)
Coppinger N.S. (MD)	Katsouras C. (GR)	Palkopoulou M. (GR)	Triantafyllidi H. (GR)
Dagre A. (GR)	Kitsiou A. (GR)	Panagoutsos S. (GR)	Triantafyllou A. (GR)
Damianaki A. (GR)	Klettas D. (GR)	Papadima E.I. (GR)	Triantis G. (GR)
Daoukou M. (GR)	Kollias A. (GR)	Papadomarkaki K. (GR)	Trikas A. (GR)
Delles C. (UK)	Kolyviras A. (GR)	Papadopoulos C. (GR)	Tsetsekou E. (GR)
Didaggelos M. (GR)	Konstantinidis D. (GR)	Papadopoulos D. (GR)	Tsiachris D. (GR)
Dimitriadis K. (GR)	Konstantinou K. (GR)	Papafaklis M. (GR)	Tsiafoutis I. (GR)
Dimitroglou I. (GR)	Korakidou A. (GR)	Papageorgaki P. (GR)	Tsigkas G. (GR)
Divani M. (GR)	Kordalis A. (GR)	Papakostopoulos K. (GR)	Tsioufis K. (GR)
Doumas M. (GR)	Kostakis P. (GR)	Papanikolaou A. (GR)	Tsioufis P. (GR)
Doundoulakis I. (GR)	Kotsis V. (GR)	Papastamatis A. (GR)	Tsoumpou I. (GR)
Drakopoulou M. (GR)	Koumeli A. (GR)	Papoutsis D. (GR)	Tziakas D. (GR)
Dri E. (GR)	Kouremeti M. (GR)	Parati G. (IT)	Tziava E. (GR)
Drogaris S. (GR)	Koutoulakis E. (GR)	Paschalinopoulos E. (GR)	Vakka A. (GR)
Elsherbiny M. (MD)	Koutouzis M. (GR)	Pathak A. (FR)	Vasilikos V. (GR)
Farmakis D. (GR)	Koutra E. (GR)	Patsilinakos S. (GR)	Vassiliadis I. (GR)
Fekas A. (GR)	Koutsakis A. (MD)	Patsourakos N. (GR)	Venetsanos D. (GR)
Filipou C. (GR)	Koutsopoulos G. (GR)	Peponaki D. (GR)	Virdis A. (IT)
Fragkiadakis K. (GR)	Kyriakoulis K. (GR)	Persu A. (BE)	Vlachogiannis G. (GR)
Fragoulis C. (GR)	Latsios G. (GR)	Petousis S. (GR)	Vordoni A. (GR)
Fragoulis E. (GR)	Lazarou A. (GR)	Petras D. (GR)	Weber T. (AT)
Gastouniotis G. (GR)	Leontsinis I. (GR)	Pirpiris N. (GR)	Weil J. (DE)
Gavrielatos G. (GR)	Liakos C. (GR)	Pittaras A. (GR)	Xenogiannis I. (GR)
Georgakila E. (GR)	Liatakis I. (GR)	Platanias K. (GR)	Zacharoulis A. (GR)
Georgiopoulos G. (GR)	Liberopoulos E. (GR)	Poikilidou M. (GR)	Zamanis I. (GR)
Gkaliagkousi E. (GR)	Loizidou V. (MD)	Polyzos D. (GR)	Zarifis I. (GR)
Gkikas A. (GR)	Lovic D. (RS)	Postadzhiyan A. (BG)	Ziakas A. (GR)
Gompos G. (GR)	Machairas N. (MD)	Poulimenos L. (GR)	
Gourlis D. (GR)	Magginas A. (GR)	Protogerou A. (GR)	
Grassi G. (IT)	Makris Th. (GR)	Raisakis K. (GR)	

# GENERAL INFORMATION

## 12th Official pre-ESH International Congress Satellite Symposium

Update on Difficult to Control Hypertension and Related Comorbidities

Chairman: **K. Tsioufis**

Co-Chairman: **R.E. Schmieder**

### Venue location & Dates

The official pre-ESH International Congress Satellite Symposium will be held from Friday, March 13th to Saturday, March 14th 2026 in Athens, at BENAKI MUSEUM (138 Piraeus str., 118 54 Athens, Greece, <http://www.benaki.gr>)

### Registration - Certificate of Attendance

The registration fee for all participants is 200,00 €. All registered participants are entitled to receive a Certificate of Attendance. The Certificate will be issued only upon display of participant badge, which will be issued by the Symposium secretariat and only upon satisfactory attendance.

### Official Language

The official language of the course is English.

### Live Streaming

<https://projector-web.gr/dromena/en/12th-pre-esh>

### Exhibition

The Symposium will be accompanied by a major exhibition where pharmaceutical and/or equipment/device industries will display relevant products and therapeutic developments.

### Organizing Bureau - Secretariat

#### Dromena Meetings & Events

169 Michalakopoulou st 11527 Athens-Greece

tel: +30 2103005545

email: [info@dromena.gr](mailto:info@dromena.gr)

[www.dromena.gr](http://www.dromena.gr)

## THANK YOU TO OUR SPONSORS



# Unidone<sup>®</sup>

δισκία  
χλωροθαλιδόνη

Ισχυρό και  
μακράς διάρκειας δράσης,  
διουρητικό θειαζιδικού τύπου<sup>1</sup>



1. Redefining Diuretics Use in Hypertension: why select a thiazide like diuretic. Review, Journal of Hypertension 2019; 37: 1574-1586

#### ΠΕΡΙΛΗΨΗ ΤΩΝ ΧΑΡΑΚΤΗΡΙΣΤΙΚΩΝ ΤΟΥ ΠΡΟΪΟΝΤΟΣ (Σ Ρ C)

**ΟΝΟΜΑΣΙΑ ΤΟΥ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ:** UNIDONE 25 mg/tab, Δισκία. **ΠΟΙΟΤΙΚΗ ΚΑΙ ΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ:** Κάθε δισκίο περιέχει 25 mg χλωροθαλιδόνης. **ΦΑΡΜΑΚΟΤΕΧΝΙΚΗ ΜΟΡΦΗ:** Δισκία. **ΚΑΙΝΙΚΕΣ ΠΛΗΡΟΦΟΡΙΕΣ:** **Θεραπευτικές ενδείξεις:** Το UNIDONE ενδείκνυται για τη θεραπεία της αρτηριακής υπέρτασης, ιδιοπαθούς ή νεφρογενούς ή μεμονωμένης συστολικής, χρόνιας σταθερής καρδιακής ανεπάρκειας ήπιου έως μέτριου βαθμού (κατηγορία II ή III σύμφωνα με την κατάταξη της NYHA). Οίδημα συγκεκριμένης προέλευσης. 1) Ασκήτης που οφείλεται σε κίρρωση του ήπατος σε σταθεροποιημένου ασθενούς υπό στενή παρακολούθηση. 2) Οίδημα λόγω νεφρωσικού συνδρόμου. Άποιος διαβήτης. **Δοσολογία και τρόπος χορήγησης:** Ενήλικες: Υπέρταση: Η συνιστώμενη δόση έναρξης είναι 25 mg/ημέρα. Σταθερή, χρόνια καρδιακή ανεπάρκεια (NYHA: λειτουργική κατηγορία II/III): Η συνιστώμενη αρχική δόση είναι 25 έως 50 mg/ημέρα, ενώ σε σοβαρές περιπτώσεις μπορεί να αυξηθεί έως και 100 mg/ημέρα. Οίδημα συγκεκριμένης προέλευσης: Συνιστάται οι δόσεις να μην υπερβαίνουν τα 50 mg/ημέρα. Άποιος διαβήτης: Αρχικά χορηγούνται 100 mg δύο φορές ημερησίως, ενώ όποτε κρινεται εφικτό προτιμάται μείωση της ημερησίας δόσης συντήρησης σε 50 mg. **Αντενδείξεις:** Ανουρία, σοβαρή ηπατική ή νεφρική ανεπάρκεια (κάθαρση κρεατινίνης <30 mL/λεπτό), ανθεκτική υποκαλιαιμία ή καταστάσεις που έχουν σαν αποτέλεσμα αυξημένη αποβολή καλίου, υπονατρίαμία και υπερασβεστιαμία, συμπτωματική υπερουριχαιμία, υπέρταση κατά τη διάρκεια της εγκυμοσύνης, νόσος του Addison που δεν έχει αντιμετωπισθεί και συγχρογούμενη θεραπεία λίθιου. **Ειδικές προειδοποιήσεις και προφυλάξεις κατά τη χρήση:** Το UNIDONE πρέπει να χρησιμοποιείται με προσοχή σε ασθενείς με έκπτωση της ηπατικής λειτουργίας ή προοδευτική ηπατική βλάβη, ασθενείς με βαριά νεφροπάθεια. **Ανεπιθύμητες ενέργειες:** Πολύ συχνές (≥1/10): κυρίως σε υψηλότερες δόσεις, υποκαλιαιμία, υπερουριχαιμία και υπερλιπιδαιμία. Συχνές (≥1/100 έως <1/10): Υπονατρίαμία, υπομαγνησισαιμία και υπεργλυκαιμία, ίλιγγος, ορθοστατική υπόταση, που μπορεί να επιδεινωθεί από ονόνημια, αναισθητικά ή κατασταλτικά, κνίδωση και άλλες μορφές εξανθήματος, στυτική δυσλειτουργία, αδυναμία.

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και αναφέρετε ΟΛΕΣ τις ανεπιθύμητες ενέργειες για ΟΛΑ τα φάρμακα συμπληρώνοντας την "ΚΙΤΡΙΝΗ ΚΑΡΤΑ".

Λ.Τ. (Unidone): 3,61 €




Pharmaceutical Laboratories S.A.



62 χρόνια UNI-PHARMA.  
Αξία για τον άνθρωπο.  
Ευθύνη για την κοινωνία.

14<sup>ο</sup> χλμ. Εθνικής Οδού 1, 145 64 Κηφισιά  
Τηλ.: 210-80 72 512, Fax: 210-80 78 907  
e-mail: uni-pharma@uni-pharma.gr

www.uni-pharma.gr



Πριν τη συνταγογράφηση απευθυνθείτε στις Περιλήψεις Χαρακτηριστικών των Προϊόντων σκανάροντας το κάτωθι QR code ή κατόπιν αιτήματος στον κάτοχο άδειας κυκλοφορίας. Καλύπτεται από τα ασφαλιστικά ταμεία. Χορηγείται με ιατρική συνταγή.

**ΛΙΑΝΙΚΕΣ ΤΙΜΕΣ**

OLARTAN F.C.TAB 10MG/TAB BTx28	6,13 €	ORIZAL F.C.TAB (20+5)MG/TAB BTx28	13,05 €
OLARTAN F.C.TAB 20MG/TAB BTx28	9,36 €	ORIZAL F.C.TAB (40+10)MG/TAB BTx28	14,56 €
OLARTAN F.C.TAB 40MG/TAB BTx28	9,40 €	ORIZAL F.C.TAB (40+5)MG/TAB BTx28	13,50 €
OLARTAN-PLUS F.C.TAB (20+12,5)MG/TAB BTx28	9,20 €	ORIZAL PLUS F.C.TAB (20+5+12,5)MG/TAB BTx28	15,76 €
OLARTAN-PLUS F.C.TAB (20+25)MG/TAB BTx28	9,20 €	ORIZAL PLUS F.C.TAB (40+10+12,5)MG/TAB BTx28	15,58 €
OLARTAN-PLUS F.C.TAB (40+12,5)MG/TAB BTx28	9,72 €	RIZAL PLUS F.C.TAB (40+10+25)MG/TAB BTx28	16,20 €
OLARTAN-PLUS F.C.TAB (40+25)MG/TAB BTx28	9,78 €	ORIZAL PLUS F.C.TAB (40+5+12,5)MG/TAB BTx28	16,00 €
		ORIZAL PLUS F.C.TAB (40+5+25)MG/TAB BTx28	16,07 €

**ΒΙΒΛΙΟΓΡΑΦΙΑ:**

1. Περίληψη Χαρακτηριστικών Προϊόντος Olartan upd 02/2025
2. Περίληψη Χαρακτηριστικών Προϊόντος Olartan Plus 20/12,5 & 20/25mg upd 02/2025
3. Περίληψη Χαρακτηριστικών Προϊόντος Olartan Plus 40/12,5 & 40/25mg upd 02/2025
4. Περίληψη Χαρακτηριστικών Προϊόντος Orizal upd 05/2025
5. Περίληψη Χαρακτηριστικών Προϊόντος Orizal Plus upd 05/2025



Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και Αναφέρετε  
 ΟΛΕΣ τις ανεπιθύμητες ενέργειες για  
 ΟΛΑ τα φάρμακα  
 Συμπληρώνοντας την "ΚΙΤΡΙΝΗ ΚΑΡΤΑ"

Με την άδεια της DAICHI SANKYO EUROPE GmbH - Γερμανία

GR-OLA-4-03-2025